Insmed (INSM) Stock Forecast & Price Target

Compare

856 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

INSM Analyst Ratings

Strong Buy

17 Buy

0 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Insmed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

INSM Stock 12 Month Forecast

Average Price Target

$109.69

▲(13.22%Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is $109.69 with a high forecast of $124.00 and a low forecast of $90.00. The average price target represents a 13.22% change from the last price of $96.88.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","125":"$125","49.25":"$49.3","74.5":"$74.5","99.75":"$99.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$124.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":109.69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$109.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$90.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,49.25,74.5,99.75,125],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.68,75.7046153846154,79.72923076923078,83.75384615384615,87.77846153846154,91.80307692307693,95.8276923076923,99.85230769230769,103.87692307692308,107.90153846153846,111.92615384615385,115.95076923076923,119.97538461538461,{"y":124,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.68,74.60384615384616,77.52769230769232,80.45153846153846,83.37538461538462,86.29923076923077,89.22307692307693,92.14692307692309,95.07076923076923,97.99461538461539,100.91846153846154,103.84230769230768,106.76615384615386,{"y":109.69,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.68,73.08923076923078,74.49846153846154,75.90769230769232,77.31692307692308,78.72615384615385,80.13538461538462,81.54461538461538,82.95384615384616,84.36307692307693,85.77230769230769,87.18153846153847,88.59076923076923,{"y":90,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.59,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.05,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.34,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.33,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.47,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.88,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.58,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$124.00

Average Price Target$109.69

Lowest Price Target$90.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$94

Hold

-2.97%

Downside

Reiterated

06/12/25

The most significant factor affecting Insmed's stock score is its financial performance, characterized by consistent losses and high leverage. Technical analysis offers a mixed outlook, with some bullish momentum but overbought conditions. Valuation remains unattractive due to negative earnings. However, recent corporate events, such as successful clinical trial results and shareholder backing, provide positive momentum.

Nicole GerminoTruist Financial

Truist Financial

$108

Buy

11.48%

Upside

Reiterated

06/11/25

Truist Financial Sticks to Their Buy Rating for Insmed (INSM)

Trung HuynhUBS

UBS

$109→$124

Buy

27.99%

Upside

Reiterated

06/11/25

UBS Remains a Buy on Insmed (INSM)

Liisa BaykoEvercore ISI

Evercore ISI

$90→$110

Buy

13.54%

Upside

Reiterated

06/11/25

Evercore ISI Sticks to Its Buy Rating for Insmed (INSM)Evercore ISI analyst Liisa Bayko raised the price target on Insmed (NASDAQ: INSM) to $110.00 (from $90.00) while maintaining a Outperform rating.

Andrew FeinH.C. Wainwright

H.C. Wainwright

$90→$120

Buy

23.86%

Upside

Reiterated

06/11/25

Buy Rating on Insmed Driven by Promising Phase 2 Results and Strategic Phase 3 Approach for PAH Treatment

Maxwell SkorMorgan Stanley

Morgan Stanley

$90→$102

Buy

5.28%

Upside

Reiterated

06/11/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: GoodRx Holdings (NASDAQ: GDRX) and Insmed (NASDAQ: INSM)

Unknown AnalystGoldman Sachs

Not Ranked

Goldman Sachs

$100→$112

Buy

15.61%

Upside

Reiterated

06/11/25

Goldman Sachs Sticks to Their Buy Rating for Insmed (INSM)

Joseph SchwartzLeerink Partners

Leerink Partners

$100→$115

Buy

18.70%

Upside

Reiterated

06/10/25

Insmed price target raised to $115 from $100 at LeerinkInsmed price target raised to $115 from $100 at Leerink

Ritu BaralTD Cowen

TD Cowen

$98→$114

Buy

17.67%

Upside

Reiterated

06/10/25

TD Cowen Reaffirms Their Buy Rating on Insmed (INSM)

Jason ZemanskyBank of America Securities

Bank of America Securities

$94→$109

Buy

12.51%

Upside

Reiterated

06/10/25

Bank of America Securities Remains a Buy on Insmed (INSM)

Leonid TimashevRBC Capital

RBC Capital

$99→$106

Buy

9.41%

Upside

Reiterated

06/10/25

Analysts' Top Healthcare Picks: Edgewise Therapeutics (EWTX), Insmed (INSM)

Stephen WilleyStifel Nicolaus

Stifel Nicolaus

$92→$110

Buy

13.54%

Upside

Reiterated

06/10/25

Stifel Nicolaus Reaffirms Their Buy Rating on Insmed (INSM)

Tiago FauthWells Fargo

Wells Fargo

$107→$119

Buy

22.83%

Upside

Reiterated

06/10/25

Insmed's TPIP Program: Promising Phase 2 Results and Market Potential Drive Buy Rating

Graig SuvannavejhMizuho Securities

Mizuho Securities

$96→$110

Buy

13.54%

Upside

Reiterated

06/10/25

Mizuho Securities Keeps Their Buy Rating on Insmed (INSM)

Kelly ShiJefferies

Jefferies

$105

Buy

8.38%

Upside

Initiated

06/08/25

Promising Phase 2 Data and Market Potential Drive Buy Rating for Insmed's TPIP in PAH Treatment

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$94

Hold

-2.97%

Downside

Reiterated

06/12/25

Nicole GerminoTruist Financial

Truist Financial

$108

Buy

11.48%

Upside

Reiterated

06/11/25

Truist Financial Sticks to Their Buy Rating for Insmed (INSM)

Trung HuynhUBS

UBS

$109→$124

Buy

27.99%

Upside

Reiterated

06/11/25

UBS Remains a Buy on Insmed (INSM)

Liisa BaykoEvercore ISI

Evercore ISI

$90→$110

Buy

13.54%

Upside

Reiterated

06/11/25

Andrew FeinH.C. Wainwright

H.C. Wainwright

$90→$120

Buy

23.86%

Upside

Reiterated

06/11/25

Buy Rating on Insmed Driven by Promising Phase 2 Results and Strategic Phase 3 Approach for PAH Treatment

Maxwell SkorMorgan Stanley

Morgan Stanley

$90→$102

Buy

5.28%

Upside

Reiterated

06/11/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: GoodRx Holdings (NASDAQ: GDRX) and Insmed (NASDAQ: INSM)

Unknown AnalystGoldman Sachs

Not Ranked

Goldman Sachs

$100→$112

Buy

15.61%

Upside

Reiterated

06/11/25

Goldman Sachs Sticks to Their Buy Rating for Insmed (INSM)

Joseph SchwartzLeerink Partners

Leerink Partners

$100→$115

Buy

18.70%

Upside

Reiterated

06/10/25

Insmed price target raised to $115 from $100 at LeerinkInsmed price target raised to $115 from $100 at Leerink

Ritu BaralTD Cowen

TD Cowen

$98→$114

Buy

17.67%

Upside

Reiterated

06/10/25

TD Cowen Reaffirms Their Buy Rating on Insmed (INSM)

Jason ZemanskyBank of America Securities

Bank of America Securities

$94→$109

Buy

12.51%

Upside

Reiterated

06/10/25

Bank of America Securities Remains a Buy on Insmed (INSM)

Leonid TimashevRBC Capital

RBC Capital

$99→$106

Buy

9.41%

Upside

Reiterated

06/10/25

Analysts' Top Healthcare Picks: Edgewise Therapeutics (EWTX), Insmed (INSM)

Stephen WilleyStifel Nicolaus

Stifel Nicolaus

$92→$110

Buy

13.54%

Upside

Reiterated

06/10/25

Stifel Nicolaus Reaffirms Their Buy Rating on Insmed (INSM)

Tiago FauthWells Fargo

Wells Fargo

$107→$119

Buy

22.83%

Upside

Reiterated

06/10/25

Insmed's TPIP Program: Promising Phase 2 Results and Market Potential Drive Buy Rating

Graig SuvannavejhMizuho Securities

Mizuho Securities

$96→$110

Buy

13.54%

Upside

Reiterated

06/10/25

Mizuho Securities Keeps Their Buy Rating on Insmed (INSM)

Kelly ShiJefferies

Jefferies

$105

Buy

8.38%

Upside

Initiated

06/08/25

Promising Phase 2 Data and Market Potential Drive Buy Rating for Insmed's TPIP in PAH Treatment

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insmed

1 Month

xxx

Success Rate

12/21 ratings generated profit

Average Return

+9.20%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +9.20% per trade.

3 Months

xxx

Success Rate

17/21 ratings generated profit

Average Return

+33.65%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.95% of your transactions generating a profit, with an average return of +33.65% per trade.

1 Year

Jason ZemanskyBank of America Securities

Success Rate

21/21 ratings generated profit

Average Return

+87.89%

reiterated a buy rating 4 days ago

Copying Jason Zemansky's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +87.89% per trade.

2 Years

xxx

Success Rate

21/21 ratings generated profit

Average Return

+158.62%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +158.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INSM Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, INSM has received 41 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. INSM average Analyst price target in the past 3 months is 109.69.

Each month's total comprises the sum of three months' worth of ratings.

INSM Financial Forecast

INSM Earnings Forecast

Next quarter’s earnings estimate for INSM is -$1.29 with a range of -$1.46 to -$1.20. The previous quarter’s EPS was -$1.42. INSM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year INSM has Preformed in-line its overall industry.

INSM Sales Forecast

Next quarter’s sales forecast for INSM is $103.14M with a range of $98.70M to $106.06M. The previous quarter’s sales results were $92.82M. INSM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 57.14% of the time in the same period. In the last calendar year INSM has Outperformed its overall industry.

INSM Stock Forecast FAQ

What is INSM’s average 12-month price target, according to analysts?

Based on analyst ratings, Insmed’s 12-month average price target is 109.69.

What is INSM’s upside potential, based on the analysts’ average price target?

Insmed has 13.22% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is INSM a Buy, Sell or Hold?

Insmed has a consensus rating of Strong Buy which is based on 17 buy ratings, 0 hold ratings and 0 sell ratings.

What is Insmed’s price target?

The average price target for Insmed is 109.69. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $124.00 ,the lowest forecast is $90.00. The average price target represents 13.22% Increase from the current price of $96.88.

What do analysts say about Insmed?

Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of INSM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Insmed (INSM) Stock Forecast & Price Target

INSM Analyst Ratings

INSM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Insmed

INSM Analyst Recommendation Trends

INSM Financial Forecast

INSM Earnings Forecast

INSM Sales Forecast

INSM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts